



In	Monthly Themes	Special Days/Holidays	Date	Twitter Copy	LinkedIn Copy	Photo /Video Asset to Accompany Post	URL	Paid Support (Amount/Flight Period)
Thought Leadership			Monday, May 01, 2023	<p>Our #DiversitAb™ platform revolutionizes the way we fight disease. Its ability to produce large scale fully-human immunoglobulins #hlgGs across multiple modalities is changing the game in antibody development. Learn more: [LINK] #SABBio #AntibodyDevelopment</p>	<p>Our DiversitAb™ platform is changing the game in antibody development with its ability to produce large scale human high-titer, high-avidity fully-human immunoglobulins #hlgGs across multiple modalities. It represents a unique targeted hlgG discovery and product development engine that can tackle complex diseases with multiple dysregulated pathways. Join us in the revolutionizing the way we fight disease with our innovative platform: [LINK]</p> <p>#SABBio #DiversitAb #AntibodyDevelopment</p>	 <p><b>Human IgG</b> Human Immunoglobulins (hlgGs) have natural multivalency that can be effective against highly mutating viruses and other diseases.</p>	<a href="https://www.sab.bio/sab-science/">https://www.sab.bio/sab-science/</a>	\$25 Twitter \$75 LinkedIn
Industry News			Tuesday, May 02, 2023					
Platform Innovation			Wednesday, May 03, 2023	HOLD for ISIRV Conference presentation	HOLD for ISIRV Conference presentation	HOLD for ISIRV Conference presentation	Presentation Page	\$25 Twitter \$75 LinkedIn
Company/PR Updates			Thursday, May 04, 2023					
			Friday, May 05, 2023	<p>#SABBio's SAB-142 has shown promising results in pre-clinical trials, offering a safer, fully-human immunoglobulin (hlgG) alternative to currently available #therapeutics for Type 1 Diabetes. Learn more about how we're innovating to improve lives! [LINK] #T1D #immunology #Biopharma</p>	<p>SAB Biotherapeutics is dedicated to revolutionizing the treatment of serious autoimmune diseases like Type 1 Diabetes through the development of innovative therapies. Our pre-clinical program, SAB-142, has demonstrated highly promising results in both preclinical safety and in vivo immunomodulatory activity. These results have enabled us to move forward with confidence towards IND filing.</p> <p>What sets SAB-142 apart from current animal-derived biologics under investigation for T1D is that it offers a fully-human alternative. This means that it provides a safer foundation for re-dosing while avoiding major immune reactions such as serum sickness. Given that millions of people worldwide are affected by T1D, we believe that this groundbreaking treatment has the potential to make a significant impact in the future of autoimmune disease treatment.</p> <p>Join us as we continue to push the boundaries of innovation in therapeutics development to improve the lives of those affected by T1D and other autoimmune diseases. Learn more about SAB-142 and our work at SAB Biotherapeutics: [LINK]</p> <p>#SABBio #T1D #Innovation #Therapeutics #immunology #Biopharma</p>	 <p><b>SAB-142</b> TYPE 1 DIABETES</p> <ul style="list-style-type: none"> <li>• First fully-human anti-thymocyte</li> <li>• Human immunoglobulin therapeutic</li> <li>• Developed for delay of the progression and onset of T1D</li> </ul>	<p>SAB 142 Page / <a href="https://www.sab.bio/sab-science/">https://www.sab.bio/sab-science/</a></p>	\$25 Twitter \$75 LinkedIn
			Saturday, May 06, 2023					
			Sunday, May 07, 2023					
			Monday, May 08, 2023	<p>#DiversitAb is a game-changer for the field of #antibody production. We're working to advance this technology to produce potent #humanIgG across multiple modalities. Learn more: [LINK] #SABBio</p>	<p>Our human immunoglobulins (hlgG) represent the first time that fully-human antibodies, produced from hyperimmunization of SAB's patented TcBovine, allow targeting to complex diseases with multiple dysregulated pathways to be fully explored as potent immunotherapies that can target multiple different targets and modes of action all in the same regulated product. This is the first scalable technology that mimics the natural way humans fight disease through production of hlgG: [LINK]</p> <p>#SABBio #Immunoglobulin #Therapeutics #BiologicalTechnology</p>	 <p><b>Polyclonal Antibody Development</b></p> <p>Human IgG antibodies allow targeting to complex diseases with multiple dysregulated pathways.</p>	<p><a href="https://vimeo.com/794173009">https://vimeo.com/794173009</a></p>	\$25 Twitter \$75 LinkedIn
			Tuesday, May 09, 2023					





			Saturday, May 27, 2023					
			Sunday, May 28, 2023					
			Monday, May 29, 2023	<p>Our groundbreaking therapy, #SAB142, is the first fully-human anti-thymocyte therapeutic that can be administered multiple times without inducing unwanted immune reactions. With potential benefits for millions living with #Type1Diabetes, we're excited to continue its development: [LINK] #SABBio #Immunotherapy #T1D</p>	<p>We are honored to be at the forefront of Type 1 Diabetes research and development. Our innovative SAB-142 program offers a fully-human anti-thymocyte hpAB therapeutic that can be administered multiple times without causing immune-related adverse reactions. In our GLP-tox study, SAB-142 induced transient lymphodepletion, confirming its mechanism of action, and potentially providing an opportunity for optimized dosing regimens.</p> <p>We're excited about the potential of SAB-142 to make a significant impact on the lives of millions of patients with Type 1 Diabetes. Join us in advancing this breakthrough therapy and stay updated on our other developments: [LINK]</p> <p>#SABBio #T1D #type1diabetes #biotech #immunology #biopharma #SAB142</p>	 <p>"SAB offers a very unique platform that has the ability to deliver for very complex diseases."</p> <p>ALEXANDRA BROPOTOVA, MD Chief Medical Officer</p>	SAB 142 Page / <a href="https://www.sab.bio/sab-science/">https://www.sab.bio/sab-science/</a>	\$25 Twitter \$75 LinkedIn
			Tuesday, May 30, 2023					
			Wednesday, May 31, 2023	<p>#SABBio transgenic cows carry the entire human IgG heavy and light chain loci, making them the only animal capable of producing fully-human antibodies. Read more: [LINK] #Therapeutics #Immunology #Biopharma</p>	<p>What sets us apart is that our transgenic cows carry the entire human IgG heavy and light chain loci, making them the only animal capable of producing fully-human antibodies. Our technology is unmatched in the field of biological technology and promises to change the landscape of immunotherapy for diseases including Influenza.</p> <p>Discover the power of our patented Tc Bovine™ and learn more about our groundbreaking approach to antibody production by visiting our website: [LINK]</p> <p>#SABBio #tcbovine #biologicaltechnology</p>	 <p>"Our platform produces targeted, high-potency, fully-human immunoglobulin (IgG) antibodies, without the need for human donors."</p> <p>EDDIE SULLIVAN, PhD Chief Executive Officer</p>	<a href="https://www.sab.bio/sab-science/">https://www.sab.bio/sab-science/</a>	\$25 Twitter \$75 LinkedIn